MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that at the Company's annual shareholder meeting on Thursday, May 19, 2011, its shareholders confirmed the reappointment of Prof. Dr. Jürgen Drews and Dr. Walter Blättler as members of the Company's Supervisory Board.
'We are pleased to announce the re-election of two experienced members of the Supervisory board and look forward to continue working with them,' commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. 'Their enormous contributions, especially in the areas of technology and product development, have been critical to MorphoSys's success.'
The shareholders of MorphoSys AG approved all management proposals put to vote at the meeting including:
- Granting full discharge to the members of the Management Board and the Supervisory Board for their activities during the business year 2010
- The appointment of PricewaterhouseCoopers AG as auditors of the Company and the MorphoSys Group for the business year 2011
- The repurchase of treasury stock up to a total of 10 % of the share capital until April 30, 2016
- The creation of a new conditional capital 2011-I to issue option and/or convertible bonds
- The amendment of compensation of the Supervisory Board by secondary payments
At the Annual General Meeting of MorphoSys AG 30.5% of the voting shares were represented.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol 'MOR'. For further information, visit http://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys; arYlaTM is a trademark of MorphoSys.